<DOC>
	<DOCNO>NCT02718950</DOCNO>
	<brief_summary>The purpose study access liraglutide influence brown adipose tissue recruitment thermogenic effect hypothalamic activation obese individual .</brief_summary>
	<brief_title>Influence Liraglutide , GLP-1 Receptor Agonist , Brown Adipose Tissue ( BAT ) Activity Humans</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Body mass index 30 kg/m2 . Hypersensitivity liraglutide vehicle component ; History diabetes prediabetes either fast glycemia , oGTT HbA1c ; Previous treatment within last 3 month glucagon like peptide1 agonist , iDPP4 medication associate BAT activation , include propranolol benzodiazepine ; Liver diseases , except nonalcoholic steatohepatitis ( NASH ) ; Infection HIV , hepatitis B hepatitis C ; Addiction cannabis , heroin , morphine , cocaine , benzodiazepine amphetamine ; Obesity induce disorder Cushing syndrome , hypothyroidism , lipodystrophy Current history treatment medication may cause significant weight gain within 3 month prior screen , include systemic corticosteroid ( except short course treatment , i.e . 7âˆ’10 day ) , tricyclic antidepressant , atypical antipsychotic mood stabilizer ( e.g . imipramine , amitriptyline , mirtazapine , paroxetine , phenelzine , chlorpromazine , thioridazine , clozapine , olanzapine , valproic acid derivative , lithium ) ; Current participation ( within last 3 month ) organize weight reduction program Currently previous use within 3 month screen pramlintide , sibutramine , orlistat , topiramate , metformin ( either prescription part clinical trial ) Participation clinical trial within last 3 month prior screen Simultaneous participation clinical trial investigational drug Previous surgical treatment obesity ; Cancer ( past present , except basal cell skin cancer squamous cell skin cancer ) , investigator 's opinion could interfere result trial Liver enzyme ( ALT AST ) 2.5 x reference range Pancreatic enzyme ( amylase , lipase ) 3 x reference range Chronic kidney disease stag 3 , 4 , 5 Relevant inflammatory acute chronic infectious disease ; hyperthyroidism ; neurological , psychiatric , gastrointestinal , respiratory , renal , hepatic cardiac relevant disease , could interfere trial result per judgment investigator Any condition discretion investigator could interfere treatment adhesion patient safety Blood donation transfusion within last 3 month Pregnancy intention pregnancy History Multiple Endocrine Neoplasia Syndrome Type 2 ( MEN 2 ) History pancreatitis Less 80 % liraglutide adherence Calcitonin reference range screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Brown Adipose Tissue</keyword>
	<keyword>Hypothalamic Activation</keyword>
	<keyword>Non-shivering Thermogenesis</keyword>
	<keyword>Basal Metabolic Rate</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Victoza</keyword>
	<keyword>Body Composition</keyword>
	<keyword>Body weight</keyword>
	<keyword>Adipose Tissue Biopsy</keyword>
</DOC>